From: The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects
Parameters | Initial Baseline2 | Day 7 | Day 21 | Δ PSE-Placebo | Day 28 | Δ PSE-Placebo |
---|---|---|---|---|---|---|
Total Cholesterol (mg/dL) | 256.0 ± 24.3 |  |  |  |  |  |
Placebo phase |  | 238.4 ± 18.8 | 239.3 ± 28.3 |  | 241.6 ± 27.2 |  |
Treatment phase |  | 239.9 ± 29.6 | 237.4 ± 29.2 | -1.9 (-1%) | 230.4 ± 22.3 | -11.2 (-5%) |
LDL (mg/dL) | 177.1 ± 22.8 |  |  |  |  |  |
Placebo phase |  | 168.5 ± 22.9 | 169.8 ± 25.6 |  | 169.4 ± 27.0 |  |
Treatment phase |  | 170.8 ± 27.7 | 157.8 ± 22.8 A, a | -12 (-7%) | 163.3 ± 27.0A | -6.1 (-4%) |
HDL (mg/dL) | 57.8 ± 19.9 |  |  |  |  |  |
Placebo phase |  | 50.4 ± 13.8 | 49.1 ± 13.6 |  | 51.2 ± 15.4 |  |
Treatment phase |  | 50.8 ± 15.5 | 53.3 ± 16.3A, a | 4.2 (9%) | 53.5 ± 16.3a | 2.3 (4%) |
Triglycerides | 125.9 ± 81.4 |  |  |  |  |  |
Placebo phase |  | 116.6 ± 60.8 | 122.7 ± 89.0 |  | 126.5 ± 74.6 |  |
Treatment phase |  | 111.4 ± 69.8 | 121.7 ± 71.4 | -1 (< -1%) | 115.7 ± 63.6 | -10.8 (-9%) |
Total Cholesterol/HDL | 4.89 ± 1.64 |  |  |  |  |  |
Placebo phase |  | 5.1 ± 1.4 | 5.2 ± 1.6 |  | 5.1 ± 1.6 |  |
Treatment phase |  | 5.1 ± 1.5 | 4.8 ± 1.6A, a | -0.4 (-8%) | 4.7 ± 1.4A, a | -0.4 (-8%) |
LDL/HDL | 3.44 ± 1.28 |  |  |  |  |  |
Placebo phase |  | 3.6 ± 1.3 | 3.6 ± 1.2 |  | 3.7 ± 1.2 |  |
Treatment phase |  | 3.7 ± 1.2 | 3.4 ± 1.2 A, a | -0.2 (-6%) | 3.3 ± 1.2A, a | -0.4 (-10%) |
CRP (mg/dL) | 0.8 ± 0.5 |  |  |  |  |  |
Placebo phase |  | 0.7 ± 0.4 | 0.7 ± 0.4 |  | 0.7 ± 0.5 |  |
Treatment phase |  | 0.8 ± 0.6 | 0.8 ± 0.5 | 0.07 (5%) | 0.7 ± 0.3 | 0 |